The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1319
A New Japanese Encephalitis Vaccine (Ixiaro)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Japanese Encephalitis Vaccine (Ixiaro)
The FDA has approved a new Japanese encephalitis vaccine (Ixiaro - Intercell/Novartis). It will replace JEVax (Sanofi Pasteur), which has had tolerability and safety problems and is no longer being manufactured.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Japanese Encephalitis Vaccine (Ixiaro)
Article code: 1319b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.